The UK KOL discusses the treatment approach for schizophrenia, generally favoring second-generation antipsychotics like cariprazine, aripiprazole, amisulpride, and lurasidone as first-line options, with first-generation agents reserved for treatment-resistant positive symptoms. The KOL also shares views on specific molecules, noting cariprazine's edge for affective and negative symptoms, lurasidone's favorable cardiometabolic profile, and the tolerability tradeoffs of paliperidone and risperidone. The interview closes with commentary on emerging options, including Cobenfy's novel muscarinic mechanism and evenamide's glutamate-modulating approach for treatment resistance.

This interview was conducted on February 18, 2026.

If you are a Datamonitor Healthcare client, you may access the interview from our KOL Insight channel.

If you are a KOL Insight subscriber, you may also access the interview from our KOL Insight portal.

Biomedtracker’s KOL Insight transcripts are available through subscription only. For more information on obtaining a KOL Insight subscription, please email Biomedtracker or call Biomedtracker Client Services at (888) 670-8900. 

For our disclosures, please read the Biomedtracker Research Standards.